Trial · NCT04323527
Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2
NCT04323527, Phase 2, Completed, Fundação de Medicina Tropical Dr. Heitor Vieira Dourado
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2. Trials, record NCT04323527. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04323527
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Chloroquine Diphosphate for the Treatment of Severe Acute Respiratory Syndrome Secondary to SARS-CoV2
- NCT number
- NCT04323527
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 278 participants, actual
- Lead sponsor
- Fundação de Medicina Tropical Dr. Heitor Vieira Dourado
- Conditions
- SARS-CoV Infection, Severe Acute Respiratory Syndrome (SARS) Pneumonia
- Interventions
- Chloroquine diphosphate
- First posted
- 2020-03-26
- Last updated
- 2021-08-09
Source ClinicalTrials.gov
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Mortality rate reduction of 50% by day 28 | 28 days after randomization | proportion of deaths at day 28 between groups compared |
| Secondary | Absolute mortality on days 7 and 14 | 7 and 14 days after first dose | number of deaths at days 7 and 14 between groups compared |
| Secondary | Improvement in overall subject's clinical status assessed in standardized clinical questionnaires on days 14 and 28 | 14 and 28 days after first dose | clinical status |
| Secondary | Improvement in daily clinical status assessed in standardized clinical questionnaires during hospitalization | during and after intervention, up to 28 days | clinical status |
| Secondary | Duration of supplemental oxygen (if applicable) | during and after intervention, up to 28 days | supplemental oxygen |
| Secondary | Duration of mechanical ventilation (if applicable) | during and after intervention, up to 28 days | mechanical ventilation |
| Secondary | Absolute duration of hospital stay in days | during and after intervention, up to 28 days | hospitalization |
| Secondary | Prevalence of grade 3 and 4 adverse events | during and after intervention, up to 28 days | adverse events grade 3 and 4 |
| Secondary | Prevalence of serious adverse events | during and after intervention, up to 28 days | adverse events |
| Secondary | Change in serum creatinine level | during and after intervention, up to 28 days | increase or decrease in serum creatinine compared to baseline |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04323527
GET https://conductscience.org/api/trials/v1/NCT04323527/registered